Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Dec 10 2021 | EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19 Industry News Industry Read More Nov 22 2021 | Bristol Myers Squibb Announces New PDUFA Date for Mavacamten Industry News In The News Industry Read More Nov 16 2021 | US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction Industry News Industry Read More Oct 15 2021 | AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial Industry News Industry Read More Aug 27 2021 | Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction Industry News Industry Read More Pagination First page « First Previous page ‹ Previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page Next › Last page Last »
Dec 10 2021 | EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19 Industry News Industry Read More
Nov 22 2021 | Bristol Myers Squibb Announces New PDUFA Date for Mavacamten Industry News In The News Industry Read More
Nov 16 2021 | US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction Industry News Industry Read More
Oct 15 2021 | AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial Industry News Industry Read More
Aug 27 2021 | Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction Industry News Industry Read More
